A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension (fimasartan)
A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
Sponsor: Asan Medical Center
This PHASE3 trial investigates Hypertension and is currently completed. Asan Medical Center leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Boryung Pharmaceutical Co., Ltd
- Bucheon St. Mary's Hospital
- Daegu Fatima Hospital
- Dong-A University
- Ewha Womans University Mokdong Hospital
- Gangnam Severance Hospital
- Hallym University Medical Center
- Hanyang University
- Jeju National University Hospital
- Kangbuk Samsung Hospital
- Konyang University Hospital
- Korea University Anam Hospital
- National Health Insurance Service Ilsan Hospital
- Sejong General Hospital
- Severance Hospital
- Soon Chun Hyang University
- Ulsan University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .